On March, 15 is awaited Nabriva Therapeutics plc (NASDAQ:NBRV)’s earnings report, according to Faxor. Analysts have anticipation on stock’s earnings per share of $-0.34. That’s up 43.33 % from last year’s $-0.6 earnings per share. Analysts at Wall Street see Nabriva Therapeutics plc’s -2.86 % EPS growth compared to $-0.35 earnings per share for previous quarter. NBRV touched $2.06 during the last trading session after $0.03 change.Nabriva Therapeutics plc is downtrending after having declined 64.09% since February 18, 2018. NBRV has 1.21 million volume or 134.27% up from normal. The stock underperformed the S&P500 by 64.09%.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans.The firm is worth $137.98 million. The firm focuses on the pleuromutilin class of antibiotics.Currently it has negative earnings. The Company’s lead product candidate is lefamulin, which has completed a Phase II clinical trial for acute bacterial skin and skin structure infections.

For more Nabriva Therapeutics plc (NASDAQ:NBRV) news published recently go to: Globenewswire.com, Nasdaq.com, Seekingalpha.com, Seekingalpha.com or Bioworld.com. The titles are as follows: “Nabriva Therapeutics Strengthens Antibiotics Leadership Position with Acquisition of Zavante Therapeutics – GlobeNewswire” published on July 24, 2018, “Implied Volatility Surging for Nabriva Therapeutics plc (NBRV) Stock Options – Nasdaq” on September 10, 2018, “Why Investors Are Bullish On Nabriva – Seeking Alpha” with a publish date: April 17, 2017, “Just How Risky Is Nabriva’s Final Trial? – Seeking Alpha” and the last “Novel approaches for effective antibiotics gather momentum – BioWorld Online” with publication date: February 14, 2019.